Psych MEQs / SAQs · Intellectual disability psychiatry
Epilepsy in intellectual disability — peri-ictal behaviour to SUDEP (MEQ)
FRANZCP-style MEQ on epilepsy in intellectual disability: McGrother epidemiology, peri-ictal formulation, Kerr-aligned joint care, seizure-aware psychotropics, SUDEP counselling.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Epidemiology. Epilepsy is far more common in ID than in the general population. McGrother et al. reported roughly 26% prevalence in adults with ID in service contact, with a large fraction still having seizures despite AEDs — matching this man's treatment-resistant pattern. Severity of ID tracks higher epilepsy rates; mortality is increased when seizures are ongoing.[1][2]
(ii) Relationships to behaviour. Map to peri-ictal timeline: pre-ictal irritability; ictal automatisms; immediate postictal confusion/aggression; postictal psychosis after cluster, often after a lucid interval (Logsdail/Toone); interictal mental illness; and AED psychiatric adverse effects (recent levetiracetam increase is highly relevant). Do not equate aggression with schizophrenia without criteria. Coexisting operant challenging behaviour may still need functional analysis.[3][4]
(iii) Acute safety. Protect from injury; follow personal epilepsy rescue plan (e.g. buccal midazolam thresholds); exclude medical drivers and nonconvulsive status if awareness does not recover. Do not stop AEDs abruptly — status risk. If postictal psychosis is suspected, prioritise safety and treat psychosis while liaising with neurology.[3][4]
(iv) Definitive management. Joint neurology–ID psychiatry review; seizure diary/video; rationalise AEDs; review levetiracetam for irritability before escalating antipsychotics; PBS and environmental strategies for non-psychotic behaviour; deprescribe risperidone if no mental illness indication once risk is controlled; if psychotropics needed, use seizure-aware choices and avoid high-risk agents such as bupropion; monitor metabolic effects of antipsychotics; capacity-supported decisions.[3][5][7]
(v) Mortality counselling. Discuss excess death risk with ongoing seizures, including SUDEP (risk rises with uncontrolled tonic–clonic and nocturnal seizures) and drowning/bathing safety, adherence supports, and night supervision strategies proportionate to risk — not fear without a plan.[2][6]
Common errors
- Stopping AEDs for behaviour.
- Ignoring levetiracetam psychiatric adverse effects.
- Treating all aggression as primary psychosis.
- Omitting SUDEP and water safety.
- Inventing foreign Mental Health Act section numbers. [3][6]
Examiner notes
Award marks for McGrother order of magnitude, lucid-interval postictal psychosis, Kerr-style joint care, and explicit SUDEP counselling. Full marks require both neurological and ID psychiatry lenses. [1][3][4][6]
References
- [1]McGrother CW, Bhaumik S, Thorp CF, et al. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications Seizure, 2006.PMID 16782360
- [2]Robertson J, Hatton C, Emerson E, Baines S Mortality in people with intellectual disabilities and epilepsy: A systematic review Seizure, 2015.PMID 26076855
- [3]Kerr M, Scheepers M, Arvio M, et al. Consensus guidelines into the management of epilepsy in adults with an intellectual disability J Intellect Disabil Res, 2009.PMID 19527434
- [4]Logsdail SJ, Toone BK Post-ictal psychoses. A clinical and phenomenological description Br J Psychiatry, 1988.PMID 3167343
- [5]Alper K, Schwartz KA, Kolts RL, Khan A Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports Biol Psychiatry, 2007.PMID 17223086
- [6]Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention Lancet Neurol, 2016.PMID 27571159
- [7]Deb S, Kwok H, Bertelli M, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities World Psychiatry, 2009.PMID 19812757